EZ Cap™ Cas9 mRNA (m1Ψ): High-Stability Capped mRNA for Mammalian Genome Editing

Executive Summary: EZ Cap™ Cas9 mRNA (m1Ψ), a product from APExBIO, is a high-purity, in vitro transcribed Cas9 mRNA incorporating a Cap1 structure for enhanced translation and stability in mammalian systems (APExBIO R1014). The use of N1-Methylpseudo-UTP (m1Ψ) and a poly(A) tail suppresses RNA-mediated innate immune activation and prolongs mRNA half-life (Cui et al., 2022). The mRNA is provided at ~1 mg/mL, 4527 nt in length, in 1 mM sodium citrate buffer (pH 6.4), and is enzymatically capped with Vaccinia capping enzymes. Cap1 structure outperforms Cap0 for translation and stability in mammalian cells (Article 2). The product is optimized for CRISPR-Cas9 genome editing workflows, supporting high-fidelity and reduced off-target effects (Article 1).

Biological Rationale

CRISPR-Cas9 genome editing relies on the precise delivery of Cas9 nuclease and guide RNA (gRNA) into target cells. Direct delivery of Cas9 mRNA bypasses the need for DNA-based expression, reducing risks of genomic integration and persistent expression that can cause off-target effects (Cui et al., 2022). Cap1-modified mRNA mimics the natural 5' end of eukaryotic mRNAs, enhancing both translation and resistance to innate immune detection (Article 4). Incorporation of N1-Methylpseudo-UTP further stabilizes the mRNA and suppresses immune activation by innate sensors such as RIG-I and MDA5. The poly(A) tail supports efficient translation initiation and mRNA stability. These features together enable transient, high-fidelity genome editing with minimized cytotoxicity and immune response.

Mechanism of Action of EZ Cap™ Cas9 mRNA (m1Ψ)

EZ Cap™ Cas9 mRNA (m1Ψ) is a single, ~4527-nucleotide mRNA encoding Streptococcus pyogenes Cas9. The mRNA is produced by in vitro transcription and enzymatically capped to generate a Cap1 structure using Vaccinia virus capping enzyme (VCE), GTP, S-adenosylmethionine (SAM), and 2′-O-methyltransferase. Cap1 adds a methyl group to the ribose of the first nucleotide, increasing translation efficiency and mRNA stability in eukaryotic cells (Cui et al., 2022). N1-Methylpseudo-UTP (m1Ψ) is incorporated to evade detection by cellular pattern recognition receptors (PRRs) and reduce activation of innate immune responses, thereby increasing mRNA half-life and translation. The poly(A) tail, typically >120 nucleotides, further enhances mRNA translation and stability by recruiting poly(A)-binding proteins.

Evidence & Benchmarks

• Cap1-modified mRNA shows higher translation efficiency and stability than Cap0 in mammalian cells (Cui et al., 2022).
• N1-Methylpseudo-UTP modification reduces activation of RIG-I and MDA5, resulting in lower induction of type I interferons in vitro (Cui et al., 2022).
• Poly(A) tail enhances mRNA stability and supports rapid translation initiation in mammalian cells (Article 4).
• Direct delivery of capped Cas9 mRNA reduces off-target editing compared to constitutive Cas9 expression (Cui et al., 2022).
• In vitro transcribed, cap1-capped mRNAs are efficiently exported from the nucleus, supporting timely Cas9 expression (Article 1).

Applications, Limits & Misconceptions

Applications:

• Transient, high-fidelity CRISPR-Cas9 genome editing in mammalian cell lines and primary cells.
• In vitro and in vivo studies requiring minimized immunogenicity and reduced off-target effects.
• Therapeutic research where genomic integration and persistent Cas9 activity are undesirable.

Limits:

• Not intended for direct addition to serum-containing media without a transfection reagent (APExBIO R1014).
• Requires strict RNase-free handling; repeated freeze-thaw cycles reduce activity.
• For research use only—not for diagnostic or therapeutic use in humans.

Common Pitfalls or Misconceptions

• EZ Cap™ Cas9 mRNA (m1Ψ) does not integrate into the genome; it provides only transient expression.
• Not suitable for direct addition to cell culture without a compatible transfection reagent, as serum nucleases rapidly degrade mRNA.
• Does not confer DNA template for homology-directed repair (HDR); separate donor DNA is required for knock-in experiments.
• Product is incompatible with diagnostic or therapeutic use in clinical applications; for in vitro research only.
• Improved stability and immune evasion may still be insufficient in some primary or immune cell types—optimization may be needed.

Workflow Integration & Parameters

EZ Cap™ Cas9 mRNA (m1Ψ) is supplied at ~1 mg/mL in 1 mM sodium citrate buffer (pH 6.4), in aliquots to prevent freeze-thaw degradation. It is recommended to store at -40°C or below, handle all materials on ice, and use RNase-free reagents and consumables. For optimal transfection, combine with a suitable reagent (e.g., electroporation or lipid-based) and avoid direct contact with serum during delivery. After co-delivery with gRNA, Cas9 protein is transiently expressed, enabling efficient genome editing within 24–48 hours. The transient nature reduces persistent nuclease activity, limiting off-target effects. For more details on integrating this reagent into advanced CRISPR workflows and optimizing editing precision, see Redefining CRISPR-Cas9 Genome Editing (this article extends mechanistic insight into mRNA engineering and nuclear export control beyond foundational workflow guidance).

Compared to DNA-based delivery, mRNA-based Cas9 reduces the risk of genomic integration and persistent expression. For a focused discussion of workflow enhancements and troubleshooting, refer to EZ Cap™ Cas9 mRNA (m1Ψ): Engineering Next-Gen Precision Genome Editing (which this article updates with new benchmarks and immune evasion data). For a primer on stability and translation efficiency, see EZ Cap™ Cas9 mRNA (m1Ψ): Precision Capped Cas9 mRNA for Genome Editing (this review is expanded here with additional Cap1 and m1Ψ functional data).

Conclusion & Outlook

EZ Cap™ Cas9 mRNA (m1Ψ) offers a robust, low-immunogenicity solution for efficient genome editing in mammalian systems. Its Cap1 structure, m1Ψ modification, and poly(A) tail collectively enhance stability, translation, and immune evasion. This reagent is optimized for transient, high-fidelity editing, making it suitable for advanced research applications where precision and safety are paramount. As the field evolves, further refinement of mRNA engineering and delivery strategies is expected to expand the scope and efficiency of CRISPR-based genome editing. For more information, visit the product page.